TY - JOUR
T1 - Efficacy and safety of T-DM1 in the 'common-practice' of HER2+ advanced breast cancer setting
T2 - A multicenter study
AU - Fabi, Alessandra
AU - De Laurentiis, Michelino
AU - Caruso, Michele
AU - Valle, Enrichetta
AU - Moscetti, Luca
AU - Santini, Daniele
AU - Cannita, Katia
AU - Carbognin, Luisa
AU - Ciccarese, Mariangela
AU - Rossello, Rosalba
AU - Arpino, Grazia
AU - Leonardi, Vita
AU - Montemurro, Filippo
AU - La Verde, Nicla
AU - Generali, Daniele
AU - Zambelli, Alberto
AU - Scandurra, Giuseppa
AU - Russillo, Michelangelo
AU - Paris, Ida
AU - D'Ottavio, Anna Maria
AU - Filippelli, Gianfranco
AU - Giampaglia, Marianna
AU - Stani, Simonetta
AU - Fabbri, Agnese
AU - Alesini, Daniele
AU - Cianniello, Daniela
AU - Giannarelli, Diana
AU - Cognetti, Francesco
PY - 2017
Y1 - 2017
N2 - Ado-trastuzumab emtansine (T-DM1) is an antibody-drug conjugate approved for the treatment of patients with human epidermal growth factor receptor 2 (HER2)- positive, metastatic breast cancer (mBC). The aim of this 'field-practice' study was to investigate the efficacy and safety of T-DM1, focusing on treatment line, previous lapatinib treatment and patterns of metastasis. Three hundred and three patients with HER2- positive mBC who received T-DM1 were identified by reviewing the medical records of 24 Italian Institutions. One hundred fourty-nine (49%) and 264 (87%) had received prior hormonal treatment and/or anti-HER2 targeted therapy, respectively. Particularly, 149 patients had been previously treated with lapatinib. The objective response rate (ORR) was 36.2%, and 44.5% when T-DM1 was administrated as second-line therapy. Considering only patients with liver metastases, the ORR was 44.4%. The median progression-free survival (PFS) was 7.0 months in the overall population, but it reached 9.0 and 12.0 months when TDM-1 was administered as second- and third-line treatment, respectively. In conclusion, in this 'real-word' study evaluating the effects of T-DM1 in patients with HER2-positive mBC who progressed on prior anti-HER2 therapies, we observed a clinicallyrelevant benefit in those who had received T-DM1 in early metastatic treatment-line and in subjects previously treated with lapatinib.
AB - Ado-trastuzumab emtansine (T-DM1) is an antibody-drug conjugate approved for the treatment of patients with human epidermal growth factor receptor 2 (HER2)- positive, metastatic breast cancer (mBC). The aim of this 'field-practice' study was to investigate the efficacy and safety of T-DM1, focusing on treatment line, previous lapatinib treatment and patterns of metastasis. Three hundred and three patients with HER2- positive mBC who received T-DM1 were identified by reviewing the medical records of 24 Italian Institutions. One hundred fourty-nine (49%) and 264 (87%) had received prior hormonal treatment and/or anti-HER2 targeted therapy, respectively. Particularly, 149 patients had been previously treated with lapatinib. The objective response rate (ORR) was 36.2%, and 44.5% when T-DM1 was administrated as second-line therapy. Considering only patients with liver metastases, the ORR was 44.4%. The median progression-free survival (PFS) was 7.0 months in the overall population, but it reached 9.0 and 12.0 months when TDM-1 was administered as second- and third-line treatment, respectively. In conclusion, in this 'real-word' study evaluating the effects of T-DM1 in patients with HER2-positive mBC who progressed on prior anti-HER2 therapies, we observed a clinicallyrelevant benefit in those who had received T-DM1 in early metastatic treatment-line and in subjects previously treated with lapatinib.
KW - Ado-trastuzumab emtansine
KW - HER2
KW - Metastatic breast cancer
KW - Taxane
KW - Trastuzumab
UR - http://www.scopus.com/inward/record.url?scp=85029932650&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85029932650&partnerID=8YFLogxK
U2 - 10.18632/oncotarget.16373
DO - 10.18632/oncotarget.16373
M3 - Article
AN - SCOPUS:85029932650
VL - 8
SP - 64481
EP - 64489
JO - Oncotarget
JF - Oncotarget
SN - 1949-2553
IS - 38
ER -